ERJ Open Research · 2020 · 32 citations · 38 references
MedicinePharmacologyPharmacotherapyPulmonary Drug DeliveryPulmonary Function TestingPulmonologyChronic Obstructive Pulmonary DiseaseCystic FibrosisInhalation TherapyMucociliary ClearancePulmonary Function AssessmentRespiratory DiseaseChronic Bronchitis TreatmentChronic Obstructive Pulmonary Disease Mucociliary ClearanceCopd PhenotypesImpaired Mucociliary ClearanceLung Function TestingMucociliary Clearance EffectsMucus Clearance EnhancementNebulized Hypertonic Saline Therapy
Background Mucus dehydration and impaired mucus clearance are common features of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In CF, inhaled hypertonic saline (HS) improves lung function and produces sustained increases in mucociliary clearance (MCC). We hypothesised that administration of HS (7% NaCl) twice daily for 2 weeks would improve clinical outcomes and produce sustained increases in MCC in COPD subjects with a chronic bronchitis (CB) phenotype. Methods Twenty-two CB subjects completed a double-blinded, crossover study comparing inhaled HS to a hypotonic control solution (0.12% saline) administered via nebuliser twice daily for 2 weeks. Treatment order was randomised. During each treatment period, symptoms and spirometry were measured. MCC was measured at baseline, shortly after initial study agent administration, and approximately 12 h after the final dose. Results HS was safe and well tolerated but overall produced no significant improvements in spirometry or patient-reported outcomes. CB subjects had slower baseline MCC than healthy subjects. The MCC rates over 60 min (Ave60Clr) in CB subjects following 2 weeks of HS were not different from 0.12% saline but were slower than baseline (Ave60Clr was 9.1±6.3% at baseline versus 5.3±6.9% after HS; p<0.05). Subgroup analyses determined that subjects with residual baseline central lung clearance (14 subjects) had improved spirometry and symptoms following treatment with HS, but not 0.12% saline, treatment. Conclusions Inhaled HS appeared to be safe in a general CB population. A specific phenotypic subgroup may benefit from HS but requires additional study.
38
Brian L. Graham, Irene Steenbruggen, Martin R. Miller et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 4.1K citations · Full text
Health Professions, Clinical Sciences, Internal Medicine +16
Small-Airway Obstruction and Emphysema in Chronic Obstructive Pulmonary Disease
John E. McDonough, Ren Yuan, Masaru Suzuki et al. · New England Journal of Medicine · 2011 · 1.2K citations · Full text
A Periciliary Brush Promotes the Lung Health by Separating the Mucus Layer from Airway Epithelia
Brian Button, Li-Heng Cai, Camille Ehré et al. · Science · 2012 · 849 citations